The average one-year price target for Sutro Biopharma (NasdaqGM:STRO) has been revised to $37.74 / share. This is an increase ...

Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Sutro Biopharma (NASDAQ:STRO) in the last three months. The following table summarizes their ...

Fintel reports that on March 24, 2026, HC Wainwright & Co. upgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from ...

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs) ...

On Thursday, Sutro Biopharma, Inc. (NASDAQ:STRO) prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline.

The condensed balance sheet as of December 31, 2023 was derived from the audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed ...

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs) ...

Detailed price information for Sutro Biopharma Inc (STRO-Q) from The Globe and Mail including charting and trades.

Sutro Biopharma (NASDAQ:STRO – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ...

Detailed price information for Sutro Biopharma Inc (STRO-Q) from The Globe and Mail including charting and trades.